Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Stephens, Philip J

Class:Id	Person:6800609
_displayName	Stephens, Philip J
_timestamp	2015-09-29 16:49:23
created	[InstanceEdit:6800610] Rothfels, Karen, 2015-09-29
firstname	Philip J
initial	PJ
surname	Stephens
(author)	[LiteratureReference:6800632] BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition [LiteratureReference:9634497] HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib [LiteratureReference:9647018] Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies [LiteratureReference:9700301] Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies [LiteratureReference:9701980] STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion [LiteratureReference:9711768] Kinase fusions are frequent in Spitz tumours and spitzoid melanomas [LiteratureReference:9711845] Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib [LiteratureReference:9831359] Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies
[Change default viewing format]

No pathways have been reviewed or authored by Stephens, Philip J (6800609)